Noncanonical WNT activation in human right ventricular heart failure

Authors: Jonathan J. Edwards, MD^{1,2}, Jeffrey Brandimarto MS², Dong-Qing Hu MD³, Sunhye Jeong, PhD², Nora Yucel, PhD², Li Li BS², Kenneth C. Bedi Jr., BS², Shogo Wada PhD², Danielle Murashige, BS², Hyun Tae Hwang³, PhD, Mingming Zhao, MD³, Kenneth B. Margulies MD², Daniel Bernstein MD³, Sushma Reddy MD³, Zoltan P. Arany MD PhD²

Affiliations

¹Division of Cardiology (J.J.E.), Children's Hospital of Philadelphia, Philadelphia, PA. ²Cardiovascular Institute (J.J.E., J.B., S.J., N.Y., L.L., K.B., S.W., D.B., K.B.M., Z.P.A.), University of Pennsylvania, Perelman School of Medicine, Philadelphia. ³Division of Cardiology, Lucile Packard Children's Hospital, (D-Q. H, H.T.H., M.Z., D.B., S.R.) Stanford University, Palo Alto, CA.

Short title: Noncanonical WNT in human RV failure

Co-Corresponding Authors:

Zoltan P. Arany Director, Cardiovascular Metabolism Program Perelman School of Medicine, University of Pennsylvania, Cardiovascular Institute 3400 Civic Blvd, Philadelphia, PA 19104. Tel: 215-898-3482 Email: zarany@pennmedicine.upenn.edu ORCID: 0000-0003-1368-2453

Jonathan J. Edwards Division of Cardiology The Children's Hospital of Philadelphia 3401 Civic Center Boulevard, 8NW90 Philadelphia, PA 19104 Tel: 215-590-3548 Fax: 215-590-5825 Email: EdwardsJ6@email.chop.edu ORCID: 0000-0002-8153-7066

Word Count: 3270

Key words: Right ventricle, Right ventricular failure, heart failure, remodeling, WNT, Calpain

- 1 **Non-standard Abbreviations:**
- CST Cell Signaling Technology
- DCM dilated cardiomyopathy
- 2 3 4 FLNA filamin A
- 5 ischemic cardiomyopathy ICM
- 6 LVF left ventricular failure
- 7 NF nonfailing
- 8 PAK1 p-21 activated kinase
- 9 pRV preserved right ventricular function
- 10 right atrial pressure RA
- 11 RA:PCWP right atrial to pulmonary capillary wedge pressure ratio
- 12 **RT-PCR** real time polymerase chain reaction
- 13 RV right ventricle
- 14 RVF right ventricular failure

1 Abstract

Background: No medical therapies exist to treat right ventricular (RV) remodeling and RV failure (RVF), in large part because molecular pathways that are specifically activated in pathologic human RV remodeling remain poorly defined. Murine models have suggested involvement of Wnt signaling, but this has not been well defined in human RVF.

6 **Methods:** Using a candidate gene approach, we sought to identify genes specifically expressed 7 in human pathologic RV remodeling by assessing the expression of 28 WNT-related genes in 8 the RVs of three groups: explanted nonfailing donors (NF, n = 29), explanted dilated and

9 ischemic cardiomyopathy, obtained at the time of cardiac transplantation, either with preserved 10 RV function (pRV, n = 78) or with RVF (n = 35).

Results: We identified the noncanonical WNT receptor ROR2 as transcriptionally strongly upregulated in RVF compared to pRV and NF (Benjamini-Hochberg adjusted p<0.05). ROR2

protein expression correlated linearly to mRNA expression ($R^2 = 0.41$, $p = 8.1 \times 10^{-18}$) among all

14 RVs, and to higher right atrial to pulmonary capillary wedge ratio in RVF (R^2 =0.40, p = 3.0x10⁻⁵).

15 We compared RVF with high and low ROR2 expression, and found that high ROR2 expression

16 was associated with increased expression of the WNT5A/ROR2/Ca²⁺ responsive protease

17 calpain, cleavage of its target FLNA, and FLNA phosphorylation, another marker of activation

downstream of ROR2. ROR2 protein expression as a continuous variable, correlated strongly to expression of calpain ($R^2 = 0.25$), total FLNA ($R^2 = 0.67$), and FLNA phosphorylation ($R^2 = 0.62$,

20 p < 0.05 for all).

21 **Conclusion**: We demonstrate robust reactivation of a fetal WNT gene program, specifically its

noncanonical arm, in human RVF characterized by activation of ROR2/calpain mediated cytoskeleton protein cleavage.

24

25 Abstract word count: 272

1 Introduction

2 Right ventricular failure (RVF) is independently predictive of morbidity and mortality in diverse 3 disease processes including left ventricular failure (LVF), pulmonary hypertension, and 4 congenital heart disease [1; 2; 3]. There is a large gap, however, in our understanding and 5 management of RVF [4]. Multiple studies demonstrate that standard reverse remodeling agents 6 that unequivocally improve survival for LVF, such as ACE inhibitors and beta-blockers, rarely 7 have impact in RVF, with sometimes even worsened outcomes [3; 5; 6; 7]. Furthermore, 8 markers of left ventricular remodeling poorly predict RV dysfunction [8]. Thus, greater 9 understanding of the fundamental mechanisms that drive RVF, different from LVF, is needed.

10

Evidence suggests that an RV-specific remodeling transcriptional program contributes to this 11 12 disparate clinical behavior of the RV and LV [9]. We chose to evaluate WNT-related differential 13 gene expression in human RV remodeling for multiple reasons. Canonical Wnt signaling 14 regulates cardiomyocyte proliferation during development, and is critical to second heart field 15 development—which gives rise to the RV—but relatively dispensable for the first heart field which gives rise to the LV [10; 11]. In parallel, noncanonical Wnt signaling promotes 16 17 developmental cardiomyocyte maturation, and knockout of downstream genes including Scrib, 18 Vangl2, or Rac1 results in second heart field structural anomalies and altered myocardial 19 patterning and cardiomyocyte cell shape that resemble those seen in pathologic remodeling [12: 20 13; 14]. In murine models of LVF and *in vitro* cardiomyocyte models, aberrant activation of both 21 canonical and non-canonical Wnt signaling has been connected to cardiomyocyte hypertrophy, 22 fibroblast proliferation and activation, activation of cytoskeleton remodeling, and activation of 23 stress pathways [15; 16; 17; 18; 19]. Unbiased transcriptomics analyses of RVF in mice due to 24 pressure or volume-overload have identified WNT signaling as a pathway that is specifically 25 altered in the progression from a compensated to decompensated state ([20; 21]. In humans, a 26 recent study illustrated that higher WNT5A serum levels and myocardial expression correlated 27 with worse RV, but not LV, systolic function and with higher likelihood of death or transplant in 28 patients with dilated cardiomyopathy (DCM) [22]. Together, these studies have suggested that 29 embryonic or fetal Wnt expression may be reactivated in RV remodeling, akin to the wellestablished reactivation of fetal programs in LV remodeling. However these and other studies 30 31 demonstrating aberrant WNT signaling in RV remodeling have been limited to transcriptomics in 32 murine models or were narrowly designed in humans such that the potential clinical role of WNT 33 signaling in adaptive and pathologic remodeling, with associated preserved function (pRV) and 34 RVF, respectively, remains incompletely defined [20; 21; 22; 23; 24]. Finally, we also focused on 35 WNT signaling because this pathway is dependent on extracellular factors and cell surface 36 receptors, potentially facilitating prognostic or therapeutic avenues that target WNT signaling in 37 RV remodeling.

38

LVF is an ideal human setting in which to characterize the gene expression signature of 39 40 adaptive and pathologic RV remodeling for two reasons. LVF is the most common cause of 41 RVF, and LVF causes a range of RV involvement—from pRV to RVF—reflecting different types 42 of adaptive/pathologic RV remodeling or different points in time in disease progression [25; 26]. 43 In this study, we leverage a large collection of human RV tissues from explanted DCM and 44 ischemic (ICM) hearts, stratified with either pRV or RVF, and from nonfailing (NF) hearts from human donors, in order to identify a robust reactivation of the fetal noncanonical WNT receptor 45 ROR2, upregulation of ROR2/Ca²⁺ responsive protease calpain, and increased cleavage of 46 47 calpain-target cytoskeletal proteins specifically in severe RVF [27; 28; 29]. We propose this 48 pathway as a potential novel therapeutic target of pathologic RV remodeling.

49

50 Materials and Methods

51

52 <u>Human samples</u>

53 Procurement of all RV myocardial tissue was performed using Gift-of-Life and University of

54 Pennsylvania Institutional Review Board (approval 802781) approved protocols with informed

1 consent provided when appropriate as previously described.[30] RV myocardial samples were 2 retrospectively obtained from the Penn Human Heart Tissue Library collected from May 2005 to 3 April 2018. DCM and ICM hearts were procured at the time of clinical heart transplantation. The 4 RV functional status (pRV vs. RVF) was identified using pretransplant right atrial (RA) pressure 5 and RA to pulmonary capillary wedge pressure ratio (RA:PCWP) as this has ratio is predictive of 6 RVF in the setting of LVF following left ventricular assist device placement in previously 7 published studies [25; 26]. Four cardiomyopathy RV hemodynamic patient groups were 8 identified based on RV hemodynamics:

- 9 DCM-RVF and ICM-RVF: $RA \ge 9$ and $RA:PCWP \ge 0.63$
- 10 DCM-pRV and ICM- pRV: $RA \le 8$ and $RA:PCWP \le 0.37$.

11 Exclusion criteria included prior ventricular assist device, retransplantation, incomplete 12 hemodynamics, or insufficient RV tissue for analysis. Potential clinical confounders to 13 differential gene expression were assessed using chi square analysis test for categorical 14 variables and Mann-Whitney U for continuous variables with pairwise deletion for any missing 15 data. Glomerular filtration rate was calculated using the MDRD equation. All reported p values 16 were adjusted using the Benjamini-Hochberg multiple comparison correction method (adjusted 17 P < 0.05 for significance).

18

Disease groups were compared to a NF cohort, selected from unused Gift-of-Life donor hearts that were deemed unsuitable for transplantation as previously described.[30] We enriched for normal RV function by selecting those with confirmed minimal tricuspid insufficiency, preserved left ventricular function by ejection fraction \geq 50%, and preserved renal function by creatinine \leq 1.2.

24

25 RNA expression

26 Total RNA was extracted from coded frozen human tissue samples using RNeasy Mini Kit 27 (Qiagen Hilden, Germany). RNA samples were diluted to 100 ng/uL by DEPC water using Qubit 28 fluorometer (Thermo Fisher Scientific Waltham, MA). Human cDNA was synthesized using MultiScribe Reverse Transcriptase[™] (Thermo Fisher Scientific). Gene expression was 29 quantified using SYBR Green Master Mix RT-PCR. RT-PCR primers (sequences in 30 31 Supplemental Table 1) were validated using primer efficiency and melt curve analyses. 32 Log2fold changes were calculated using the housekeeping genes GAPDH and TBP. Candidate 33 genes were first assessed for differential expression in both DCM and ICM using Kruskal-Wallis 34 test to compare log2fold (adjusted p < 0.05) between NF/pRV/RVF for both the DCM and ICM 35 cohorts. Genes that were differentially expressed for both DCM and ICM were assessed for 36 differential expression between pRV and RVF using Mann Whitney test after combining DCM 37 and ICM groups.

38

39 Protein expression

40 Genes that demonstrated statistically significant differential expression between pRV and RVF 41 were further assessed using western blot to evaluate differential protein expression. As a 42 preliminary analysis, four representative samples from each group were selected using the lowest and highest RA:RPCW ratio for pRV and RVF, respectively, and the lowest NPPA 43 44 expression for the NF controls. Protein extraction was performed using NE-PER[™] kit (ThermoFisher Scientific) to separate cytoplasmic and nuclear fractions. Equal amount 45 46 cytoplasmic or nuclear protein according to predicted protein location from each sample was 47 separated by SDS-PAGE. Western blot was performed using monoclonal antibodies to the 48 following targets: CREBBP (Cell Signaling Technology (CST) Danvers, MA, cat D6C5), 49 NFATC2 (Abcam, Cambridge, UK, cat ab2722), ROR2 (CST cat D3B6F), TBP (Abcam, cat ab51841), HDAC2 (Abcam, cat ab32117), and GAPDH (CST, cat D16H11). Given preliminary 50 51 results demonstrating significant upregulation of ROR2, western blots were performed for all 52 remaining samples. In a subset of RVF samples with either highest (n = 6) or lowest (n = 6)53 ROR2 expression, we performed total protein extraction using RIPA to explore activation of 54 downstream pathways. Western blot was performed using antibodies to filamin A (FLNA, CST

cat 4762), serine-2152 phosphorylated FLNA (CST cat 4761), calpain (CST cat 2556),
 phosphorylated PAK1 (CST cat 2601), and spectrin (Biolegend, San Diego, CA cat D8B7).
 Secondary anti-mouse (CST cat 7076) and anti-rabbit (CST cat 7074) were used as indicated.
 Densitometry was assessed using SuperSignal[™] West Femto enhanced chemiluminescent
 substrate (ThermoFisher Scientific) and ImageStudio (LI-COR Biotechnology, Lincoln,
 Nebraska).

7

8 <u>Statistics</u>

All data was analyzed using RStudio version 1.1.463. Data are presented as median (interquartile range), count (%), or adjusted R^2 for correlations. Pairwise deletion was performed for any missing clinical data. Statistical significance was determined using Mann Whitney U or Kruskal-Wallis, where appropriate, for continuous variables, and chi square for categorical variables. All reported p values were adjusted using the Benjamini-Hochberg multiple comparison correction method (adjusted P < 0.05 for significance).

15

16 **Results**

17 Patient characteristics

We collected RV myocardial tissue from patients undergoing clinical heart transplantation for LVF due to DCM or ICM and separated them according to the presence of pRV or RVF using preexplant hemodynamic data, as described in the methods. Median time between hemodynamic data collection and explantation was 28.5 days (interquartile range: 13 – 53 days). In total, we identified 47 DCM-pRV, 26 DCM-RVF, 31 ICM-pRV, and 9 ICM-RVF, representing the largest and most clinically diverse study of human RV differential gene expression in LVF to date.

25

26 We identified no clinical confounders between DCM-pRV/DCM-RVF, ICM-pRV/ICM-RVF, and 27 combined pRV/RVF groups (Table 1 and Supplemental Table 2), including no differences in 28 gender, age, ethnicity, body surface area, body weight, heart weight, renal function by 29 glomerular filtration rate, diabetes, use of reverse remodeling agents collectively or individually 30 (ACE inhibitor, angiotensin receptor blocker, or β -blocker), use of other cardioactive medications 31 (digoxin, diuretics, calcium channel blockers, or milrinone), lipid lowering medications, thyroid 32 medications, or pacemakers. Also, ICM-RVF hearts were no more likely to have significant right 33 coronary artery disease (\geq 70% stenosis) or history of prior coronary intervention compared to 34 their ICM-pRV counterparts, indicating that any observed transcriptional changes could not be 35 attributable to dichotomous coronary involvement.

36

The NF group was similarly well matched across all four cardiomyopathy hemodynamic groups with respect to age, ethnicity, body surface area, and weight, although not for gender (**Supplemental Table 3**). Previous unbiased studies of cardiac DGE have demonstrated few gender-specific differences, and none in WNT-related gene expression, suggesting a low likelihood that gender differences would impact our findings [31].

42

43 WNT Pathway Candidate Gene Analysis

44 RNA expression

In total, we assessed the RV myocardial expression of 28 WNT-related genes including ligands, 45 46 receptors and co-receptors, inhibitors, and downstream signaling and transcriptional targets that 47 have been either previously implicated in RV remodeling in murine models of RVF or have a 48 known interaction based on literature review (Supplemental Table 3). First, we assessed 49 whether these 28 WNT-related genes and two well described heart failure genes-NPPA and 50 NPPB—exhibited differential expression between NF/pRV/RVF separately for both DCM and 51 ICM using Kruskal-Wallis to compare log₂fold changes.[32] Most WNT-related genes 52 (Supplemental Table 4) and both natriuretic peptides demonstrated statistically significant 53 differential expression in at least DCM or ICM, with 12 demonstrating differential expression in 54 both: AXIN2, CREBBP, DAAM2, FZD1, FZD7, NFATC2, NPPA, ROR2, SFRP1, SFRP3,

1 WISP2, and WNT10B. Of these 12, only five genes were found to be differentially expressed 2 between pRV and RVF: CREBBP, NFATC2, NPPA, ROR2, and WISP2 (Table 2, Figure 1). To 3 further prioritize these candidate genes, we performed linear regressions comparing RNA 4 expression to RA:PCWP and found that ROR2 ($R^2 = 0.16$, $p = 3.2 \times 10^{-5}$), CREBBP ($R^2 = 0.03$, 5 p = 0.048), and NFATC2 ($R^2 = 0.03$, p = 0.048) had modest correlations with the RA:PCWP, 6 while WISP2 did not ($R^2 = 0.01$, p = 0.14).

7

8 Protein expression

9 To assess whether protein expression would correlate with the observed transcriptional 10 upregulation of CREBBP, NFATC2, and ROR2 in RVF, we first performed a preliminary analysis comparing four representative samples from each group representing the hemodynamic 11 12 extremes for pRV and RVF and the lowest NPPA expression for NF. In this preliminary analysis, 13 strong ROR2 protein expression was observed in the DCM-RVF samples with minimal 14 expression in the other groups (Supplemental Figure 1). A similarly dramatic relationship was 15 not observed for the other targets; we thus prioritized ROR2 for protein expression analysis in 16 the remaining 123 samples.

17

18 ROR2 protein expression in all 143 samples correlated strongly with RNA expression (R^2 = 0.41, $p = 8.1 \times 10^{-18}$). Median and average RVF-to-pRV fold increase in protein expression were 19 20 2.0 and 4.5, respectively, (p < 0.05, **Figure 2**). Furthermore, particularly within the RVF group, 21 ROR2 protein expression increased linearly with higher RA:PCWP ($R^2 = 0.40$, $p = 3.0 \times 10^{-5}$, Figure 2). Finally, by using the NF ROR2 RNA and protein expression to establish normative 22 ranges, RVF samples demonstrated a greater than 3-fold odds (95th percentile confidence 23 intervals) of expressing ROR2 above the 95th percentile compared to pRV (protein: OR 3.07 24 25 (1.1 - 8.4), p = 0.03; RNA: OR 3.18 (1.4 - 7.3), p = 0.0071). In summary, ROR2 expression, 26 both RNA and protein, correlates directly with RVF categorically, and with worse RV 27 hemodynamics.

28

29 Impact of ROR2 expression in RVF

30 ROR2 expression correlates with actin cytoskeletal remodeling pathways

31 We next explored what functional impact higher ROR2 expression might have in the setting of 32 RVF by assessing overall expression and phosphorylation of downstream targets, focusing on 33 cytoskeletal remodeling pathways. Normalized to GAPDH, we found a roughly 1.5 to 2-fold 34 increase in calpain, full length FLNA, and full length spectrin protein expression in high ROR2 35 expressing RVF patients compared to low ROR2 expression (Figure 3 and Table 3, p < 0.05. 36 for all). Similarly, we identified an almost 8- and 3-fold increase in the calpain cleavage-37 mediated FLNA (180 kDa) and spectrin (150 kDa) breakdown products, respectively. 38 Phosphorylation of FLNA serine-2152 modulates its mechanosensitive interaction with integrin 39 and inhibits calpain-mediated cleavage, and ROR2 overexpression in HEK293 cells was found 40 to activate one of the known kinases for this site-p21-activated kinase (PAK1)-through a 41 presumed indirect phosphorylation.[33; 34; 35] We therefore assessed the relationship of ROR2 42 expression, FLNA phosphorylation, and phosphorylated PAK1 expression. In high ROR2 43 expressing RVF samples, we observed a nearly 10-fold increase in FLNA phosphorylation 44 normalized to total FLNA and a 2-fold increase in phosphorylated PAK1 normalized to GAPDH 45 (p < 0.05, both). Given these consistent relationships observed categorically for high and low 46 ROR2 expression, we next assessed whether expression of these targets correlated linearly or 47 logarithmically with ROR2 expression (Figure 3 and Table 3). The most statistically significant 48 correlation observed was a logarithmic increase in phosphorylated PAK1 with increasing ROR2 49 expression ($R^2 = 0.83$, $p = 1.4 \times 10^{-4}$). Full length and phosphorylated FLNA also correlated 50 significantly in a logarithmic relationship with ROR2 expression ($R^2 = 0.67$ and 0.62, 51 respectively, p <0.003). Calpain expression correlated linearly with ROR2 expression ($R^2 = 0.66$, 52 p = 0.0018). In summary, within the context of RVF, high ROR2 expression correlates with 53 calpain expression and calpain-mediated cleavage as well as an increase in total FLNA, FLNA

54 phosphorylation, and total spectrin expression.

1 2 **Discussion**

To date, there are no evidence-supported therapies that target RVF [9]. Our lack of understanding of the molecular mechanisms that regulate RV remodeling in humans, particularly with respect to adaptive compared to pathologic remodeling, remains a significant barrier towards achieving this goal. Here, we find compelling evidence that non-canonical WNT signaling, and in particular ROR2 signaling, is aberrantly activated in human RVF.

8

9 ROR2 is a cell surface receptor tyrosine kinase that transmits noncanonical WNT signaling 10 following binding of its only known ligand—WNT5A—via planar cell polarity, WNT/Ca²⁺, and stress pathways including JNK/cJUN [36]. ROR2 is broadly expressed during embryogenesis, 11 12 being critical to cardiac, skeletal, and sympathetic nervous system development, but is silent in 13 most healthy postnatal tissue [27; 28; 37]. Global knockout of Ror1 reveals no apparent defects 14 in the developing mouse, but knockout of Ror2 resulted in ventricular septal defects and 15 knockout of both Ror2 and Ror1 led to construncal type congenital heart defects [27]. 16 Interestingly, upon our review of their published histology, we noted a significantly 17 noncompacted appearance to the RV and LV myocardium only in the double knockout, which 18 suggests Ror1/2 play a role in myocardial development similar to other noncanonical WNT 19 genes (e.g. disorganized and noncompacted myocardium with loss of Daam1, Scrib1, or 20 second heart field-specific loss of Rac1) [12; 13; 14]. ROR2 in disease has been largely studied 21 in the context of tumors, where WNT5A/ROR2 signaling leads to activation of calpain-mediated 22 cleavage, cytoskeletal rearrangement for purposes of migration, and as a hypoxia-inducible 23 factor downstream of VHL/HIF signaling with implications in tumor invasiveness and metastasis 24 [29; 38; 39]. To date, little is known about the role of ROR2 reactivation in cardiac pathology. In 25 a rat left anterior descending ligation myocardial infarction model, increased protein levels of 26 Wnt5a, Ror2, and Vangl2-one if its immediate downstream targets-were observed in the 27 remote vital area [40]. Using neonatal rat ventricular myocytes (NRVMs), the authors identified 28 phosphorylation of cJun and Jnk as mediators of this activation. Another group found that 29 Wnt5a stimulation of NRVMs caused hypertrophy, cytoskeletal rearrangement, and mPTP opening, but any dependence on Ror2 or other known Wnt5a receptors was not tested [41]. Our 30 31 results are thus consistent with, and expand on, what few mechanistic data exist on the role of 32 ROR2 in myocardial remodeling, and suggest that ROR2 induction in RVF mechanistically 33 contributes to the pathogenesis of human RVF.

34

35 By comparing RVF with high and low ROR2 expression, we found evidence that in the context 36 of RVF ROR2 activation leads to increased calpain-mediated cleavage of FLNA. FLNA is a 37 large scaffolding cytoskeletal protein that is involved in broad cellular functions including 38 maintaining cell and tissue structure (e.g. cross-linking actin filaments, binding integrin, 39 maintaining adherens junctions), cell migration, and as a signaling molecule via nuclear 40 translocation of cleaved fragments [42]. Loss of FLNA in humans or mice causes early lethality 41 with diverse and severe developmental defects affecting the heart, lung, neurologic system, and 42 skeleton [43]. Of note, severe RV myocardial noncompaction has been previously reported in a 43 patient with a FLNA G1728C mutation [44]. FLNA has been connected to ROR2 in cells other 44 than cardiomyocytes. For example, in melanoma cells, ROR2-FLNA interaction is critical for 45 WNT5A-induced JNK phosphorylation, cytoskeleton remodeling, and cell migration, and 46 WNT5A-ROR2 binding induces calpain expression and its cleavage of FLNA leading to 47 increased invasiveness [29; 45]. Importantly, there is also evidence that calpain contributes to 48 pathologic RV remodeling. In an acute pressure overload-induced rabbit RVF model, direct right 49 coronary artery infusion of the selective calpain inhibitor MDL-28710 partially rescued RV 50 function and reduced cleavage of the cytoskeletal protein talin [46]. Thus, our findings of ROR2 51 induction and activation of its downstream pathways, suggest a model (Figure 4) whereby an 52 embryonic WNT5a/ROR2 program is reactivated in the setting of RVF, which then promotes 53 calpain-mediated cleavage of FLNA and likely other targets, ultimately leading to maladaptive 54 cytoskeletal changes and worsening RVF.

1 2 Limitations

3 There may have been some disease progression or clinical deterioration in the time interval 4 between tissue collection and hemodynamic assessments for DCM and ICM RV, although if so, 5 such changes would likely have introduced variability and weakened our differential expression 6 analyses. It is also possible that changes in gene expression occurred during the period 7 between heart harvest and tissue freezing, although this process is highly controlled by the 8 Penn Human Heart Tissue Library with standard operating procedures including assiduous 9 adherence to cold cardioplegia and snap freezing samples in liquid nitrogen. Our use of rare 10 human-derived tissue allowed us to examine differential expression in a natural setting, but it did 11 limit our ability to mechanistically evaluate the impact of altered ROR2 expression. Thus, further 12 work will be necessary such as testing the response to RV pressure or volume overload in Ror2 13 gain-of-function and loss-of-function mice.

14

15 Conclusions

In this study, using one of the largest and most diverse existing libraries of human heart tissue, we found that WNT signaling is broadly dysregulated in RV remodeling in the setting of ICM and DCM. We found a large reactivation of embryonic ROR2 RNA and protein expression in RVF, which correlated with worse RV hemodynamics, and with activation of a downstream pathway of increased calpain expression and FLNA cleavage. Taken together, the data reveal the robust activation of noncanonical WNT signaling in human RVF, and identify ROR2 as a potential novel RVF therapeutic target that may suppress cytoskeletal remodeling.

24 Data Availability Statement

All datasets generated and analyzed for the current study are available in supplementary material.

27

28 Ethics Statement

29 Procurement of all RV myocardial tissue was performed using Gift-of-Life and University of

- 30 Pennsylvania Institutional Review Board (approval 802781) approved protocols with informed
- 31 consent provided when appropriate. The authors attest they are in compliance with human
- 32 studies committees of the authors' institutions and Food and Drug Administration guidelines,
- including patient consent where appropriate.

35 Author contributions

Conceptualization and Design (JJE, KBM, DB, SR, ZPA). Acquisition of data (JJE, JB, LL, DQH,
KCB, DM, HTH, MZ). Analysis and interpretation of data (JJE, JB, SJ, NY, SW, SR, ZPA).
Writing and editing of manuscript (JJE, SJ, KBM, SR, ZPA).

39

40 Conflicts of Interest

41 The authors have no relationships relevant to the content of this paper to disclose.

42

43 Acknowledgements

44 The authors acknowledge all patients and donors who provided tissue without which this study 45 could not have been performed. The authors acknowledge the Gift-of-Life Donor Program 46 Philadelphia, PA who helped provide access to nonfailing tissue from unused donor hearts. A 47 previous version of this manuscript was submitted to the preprint server medRxiv

47 previous version of this manuscript was 48 (https://doi.org/10.1101/2020.07.03.20134965).

49

50 Sources of Funding

- 51 This study was supported by grants from NIH and National Heart, Lung, and Blood Institute
- 52 (NHLBI) 152446 (to Z.PA.), K08 HL127277-01 (to S.R.), and R01 HL105993 (to K.B.M), and
- 53 Department of Defense W81XWH18-1-0503 (to Z.P.A.) and PR151448 (to DB and SR). JJE

- 1 was supported by NIH 5T32HL007915, Matthew's Heart of Hope, and Congenital Heart Disease
- 2 3 Coalition.

1	Deferences
1	References
2	[1] S.A. van Wolferen, J.T. Marcus, A. Boonstra, K.M. Marques, J.G. Bronzwaer, M.D.
3	Spreeuwenberg, et. al., Prognostic value of right ventricular mass, volume, and function
4	in idiopathic pulmonary arterial hypertension. Eur Heart J 28 (2007) 1250-7.
5	[2] S. Piran, G. Veldtman, S. Siu, G.D. Webb, and P.P. Liu, Heart failure and ventricular
6	dysfunction in patients with single or systemic right ventricles. Circulation 105 (2002)
7	1189-94.
8	[3] S.V. Babu-Narayan, A. Uebing, P.A. Davlouros, M. Kemp, S. Davidson, K. Dimopoulos, et.
9	al., Randomised trial of ramipril in repaired tetralogy of Fallot and pulmonary
10	regurgitation: the APPROPRIATE study (Ace inhibitors for Potential PRevention Of the
11	deleterious effects of Pulmonary Regurgitation In Adults with repaired TEtralogy of
12	Fallot). Int J Cardiol 154 (2012) 299-305.
13	[4] N.F. Voelkel, R.A. Quaife, L.A. Leinwand, R.J. Barst, M.D. McGoon, D.R. Meldrum, et al.,
14	Molecular Mechanisms of Right Heart, Right ventricular function and failure: report of a
15	National Heart, Lung, and Blood Institute working group on cellular and molecular
16	mechanisms of right heart failure. Circulation 114 (2006) 1883-91.
17	[5] L. Dos, S. Pujadas, M. Estruch, A. Mas, I. Ferreira-Gonzalez, A. Pijuan, et. al., Eplerenone in
18	systemic right ventricle: double blind randomized clinical trial. The evedes study. Int J
19	Cardiol 168 (2013) 5167-73.
20	[6] A.R. Doughan, M.E. McConnell, and W.M. Book, Effect of beta blockers (carvedilol or
21	metoprolol XL) in patients with transposition of great arteries and dysfunction of the
22	systemic right ventricle. Am J Cardiol 99 (2007) 704-6.
23	[7] R.E. Shaddy, M.M. Boucek, D.T. Hsu, R.J. Boucek, C.E. Canter, L. Mahony, et. al., Pediatric
24	Carvedilol Study, Carvedilol for children and adolescents with heart failure: a
25	randomized controlled trial. JAMA 298 (2007) 1171-9.
26	[8] T.G. di Salvo, K.C. Yang, E. Brittain, T. Absi, S. Maltais, and A. Hemnes, Right ventricular
27	myocardial biomarkers in human heart failure. J Card Fail 21 (2015) 398-411.
28	[9] S.L. Roche, and A.N. Redington, Right ventricle: wrong targets? Another blow for
29	pharmacotherapy in congenital heart diseases. Circulation 127 (2013) 314-6.
30	[10] E.D. Cohen, Z. Wang, J.J. Lepore, M.M. Lu, M.M. Taketo, D.J. Epstein, et. al., Wnt/beta-
31	catenin signaling promotes expansion of IsI-1-positive cardiac progenitor cells through
32	regulation of FGF signaling. J Clin Invest 117 (2007) 1794-804.
33	[11] A. Pahnke, G. Conant, L.D. Huyer, Y. Zhao, N. Feric, and M. Radisic, The role of Wnt
34	regulation in heart development, cardiac repair and disease: A tissue engineering
35	perspective. Biochem Biophys Res Commun 473 (2016) 698-703.
36	[12] C. Leung, X. Lu, M. Liu, and Q. Feng, Rac1 signaling is critical to cardiomyocyte polarity
37	and embryonic heart development. J Am Heart Assoc 3 (2014) e001271.
38	[13] H.M. Phillips, H.J. Rhee, J.N. Murdoch, V. Hildreth, J.D. Peat, R.H. Anderson, et. al.,
39	Disruption of planar cell polarity signaling results in congenital heart defects and
40	cardiomyopathy attributable to early cardiomyocyte disorganization. Circ Res 101 (2007)
41	137-45.
42	[14] D. Li, M.A. Hallett, W. Zhu, M. Rubart, Y. Liu, Z. Yang, et. al., Dishevelled-associated
43	activator of morphogenesis 1 (Daam1) is required for heart morphogenesis.
44	Development 138 (2011) 303-15.
45	[15] L.M. Iyer, S. Nagarajan, M. Woelfer, E. Schoger, S. Khadjeh, M.P. Zafiriou, et. al., A
46	context-specific cardiac beta-catenin and GATA4 interaction influences TCF7L2
47	occupancy and remodels chromatin driving disease progression in the adult heart.
48	Nucleic Acids Res 46 (2018) 2850-2867.
49	[16] J. Qu, J. Zhou, X.P. Yi, B. Dong, H. Zheng, L.M. Miller, et. al., Cardiac-specific
50	haploinsufficiency of beta-catenin attenuates cardiac hypertrophy but enhances fetal
51	gene expression in response to aortic constriction. J Mol Cell Cardiol 43 (2007) 319-26.
52	[17] M.I. Oerlemans, M.J. Goumans, B. van Middelaar, H. Clevers, P.A. Doevendans, and J.P.
53	Sluijter, Active Wht signaling in response to cardiac injury. Basic Res Cardiol 105 (2010)
54	631-41.

- [18] L. Barandon, T. Couffinhal, J. Ezan, P. Dufourcq, P. Costet, P. Alzieu, et. al., Reduction of infarct size and prevention of cardiac rupture in transgenic mice overexpressing FrzA. Circulation 108 (2003) 2282-9.
 [19] S. Zuo, W.K. Jones, H. Li, Z. He, Z. Pasha, Y. Yang, et. al., Paracrine effect of Wnt11-
- [19] S. Zuo, W.K. Jones, H. Li, Z. He, Z. Pasha, Y. Yang, et. al., Paracrine effect of Wnt11 overexpressing mesenchymal stem cells on ischemic injury. Stem Cells Dev 21 (2012)
 598-608.
- 598-608.
 [20] T. Urashima, M. Zhao, R. Wagner, G. Fajardo, S. Farahani, T. Quertermous, et. al.,
 Molecular and physiological characterization of RV remodeling in a murine model of pulmonary stenosis. Am J Physiol Heart Circ Physiol 295 (2008) H1351-H1368.
- [21] S. Reddy, M. Zhao, D.Q. Hu, G. Fajardo, E. Katznelson, R. Punn, et. al., Physiologic and
 molecular characterization of a murine model of right ventricular volume overload. Am J
 Physiol Heart Circ Physiol 304 (2013) H1314-27.
- [22] A. Abraityte, I.G. Lunde, E.T. Askevold, A.E. Michelsen, G. Christensen, P. Aukrust, et. al.,
 Wnt5a is associated with right ventricular dysfunction and adverse outcome in dilated
 cardiomyopathy. Sci Rep 7 (2017) 3490.
- [23] J.L. Williams, O. Cavus, E.C. Loccoh, S. Adelman, J.C. Daugherty, S.A. Smith, et. al.,
 Defining the molecular signatures of human right heart failure. Life Sci 196 (2018) 118 126.
- [24] A. Gaertner, P. Schwientek, P. Ellinghaus, H. Summer, S. Golz, A. Kassner, et. al.,
 Myocardial transcriptome analysis of human arrhythmogenic right ventricular
 cardiomyopathy. Physiol Genomics 44 (2012) 99-109.
- [25] R.L. Kormos, J.J. Teuteberg, F.D. Pagani, S.D. Russell, R. John, L.W. Miller, et. al., Right
 ventricular failure in patients with the HeartMate II continuous-flow left ventricular assist
 device: incidence, risk factors, and effect on outcomes. J Thorac Cardiovasc Surg 139
 (2010) 1316-24.
- [26] E.W. Grandin, P. Zamani, J.A. Mazurek, G.S. Troutman, E.Y. Birati, E. Vorovich, et. al.,
 Right ventricular response to pulsatile load is associated with early right heart failure and
 mortality after left ventricular assist device. J Heart Lung Transplant 36 (2017) 97-105.
- [27] M. Nomi, I. Oishi, S. Kani, H. Suzuki, T. Matsuda, A. Yoda, et. al., Loss of mRor1 enhances
 the heart and skeletal abnormalities in mRor2-deficient mice: redundant and pleiotropic
 functions of mRor1 and mRor2 receptor tyrosine kinases. Mol Cell Biol 21 (2001) 8329 35.
- [28] K. Morioka, C. Tanikawa, K. Ochi, Y. Daigo, T. Katagiri, H. Kawano, et. al., Orphan receptor
 tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci
 100 (2009) 1227-33.
- [29] M.P. O'Connell, J.L. Fiori, K.M. Baugher, F.E. Indig, A.D. French, T.C. Camilli, et. al.,
 Wnt5A activates the calpain-mediated cleavage of filamin A. J Invest Dermatol 129
 (2009) 1782-9.
- [30] C.Y. Chen, M.A. Caporizzo, K. Bedi, A. Vite, A.I. Bogush, P. Robison, et. al., Suppression
 of detyrosinated microtubules improves cardiomyocyte function in human heart failure.
 Nat Med 24 (2018) 1225-1233.
- [31] K. InanlooRahatloo, G. Liang, D. Vo, A. Ebert, I. Nguyen, and P.K. Nguyen, Sex-based
 differences in myocardial gene expression in recently deceased organ donors with no
 prior cardiovascular disease. PLoS One 12 (2017) e0183874.
- [32] A.C. Houweling, M.M. van Borren, A.F. Moorman, and V.M. Christoffels, Expression and
 regulation of the atrial natriuretic factor encoding gene Nppa during development and
 disease. Cardiovasc Res 67 (2005) 583-93.
- [33] H.S. Chen, K.S. Kolahi, and M.R. Mofrad, Phosphorylation facilitates the integrin binding of
 filamin under force. Biophys J 97 (2009) 3095-104.
- [34] M. Chen, and A. Stracher, In situ phosphorylation of platelet actin-binding protein by cAMP dependent protein kinase stabilizes it against proteolysis by calpain. J Biol Chem 264
 (1989) 14282-9.

1 [35] K.Y. Goh, N.W. Ng, T. Hagen, and T. Inoue, p21-activated kinase interacts with Wnt 2 3 4 signaling to regulate tissue polarity and gene expression. Proc Natl Acad Sci U S A 109 (2012) 15853-8. [36] S. Stricker, V. Rauschenberger, and A. Schambony, ROR-Family Receptor Tyrosine 5 6 Kinases. Curr Top Dev Biol 123 (2017) 105-142. [37] S. Takeuchi, K. Takeda, I. Oishi, M. Nomi, M. Ikeya, K. Itoh, et. al., Mouse Ror2 receptor 7 tyrosine kinase is required for the heart development and limb formation. Genes Cells 5 8 (2000) 71-8. 9 [38] T.M. Wright, and W.K. Rathmell, Identification of Ror2 as a hypoxia-inducible factor target 10 in von Hippel-Lindau-associated renal cell carcinoma. J Biol Chem 285 (2010) 12916-24. 11 [39] C.M. Yang, S. Ji, Y. Li, L.Y. Fu, T. Jiang, and F.D. Meng, Ror2, a Developmentally 12 Regulated Kinase, Is Associated With Tumor Growth, Apoptosis, Migration, and Invasion 13 in Renal Cell Carcinoma. Oncol Res 25 (2017) 195-205. 14 [40] M. Hagenmueller, J.H. Riffel, E. Bernhold, J. Fan, H.A. Katus, and S.E. Hardt, Dapper-1 is 15 essential for Wnt5a induced cardiomyocyte hypertrophy by regulating the Wnt/PCP 16 pathway. FEBS Lett 588 (2014) 2230-7. 17 [41] P. Zhang, C. Hu, Y. Li, Y. Wang, L. Gao, K. Lu, et. al., Vangl2 is essential for myocardial 18 remodeling activated by Wnt/JNK signaling. Exp Cell Res 365 (2018) 33-45. 19 [42] J. Yue, S. Huhn, and Z. Shen, Complex roles of filamin-A mediated cytoskeleton network in 20 cancer progression. Cell Biosci 3 (2013) 7. 21 [43] Y. Feng, M.H. Chen, I.P. Moskowitz, A.M. Mendonza, L. Vidali, F. Nakamura, et. al., 22 Filamin A (FLNA) is required for cell-cell contact in vascular development and cardiac 23 morphogenesis. Proc Natl Acad Sci U S A 103 (2006) 19836-41. 24 [44] M. Zenker, L. Nahrlich, H. Sticht, A. Reis, and D. Horn, Genotype-epigenotype-phenotype 25 correlations in females with frontometaphyseal dysplasia. Am J Med Genet A 140 (2006) 26 1069-73. 27 [45] A. Nomachi, M. Nishita, D. Inaba, M. Enomoto, M. Hamasaki, and Y. Minami, Receptor 28 tyrosine kinase Ror2 mediates Wnt5a-induced polarized cell migration by activating c-29 Jun N-terminal kinase via actin-binding protein filamin A. J Biol Chem 283 (2008) 27973-30 81. 31 [46] H.A. Ahmad, L. Lu, S. Ye, G.G. Schwartz, and C.R. Greyson, Calpain inhibition preserves 32 talin and attenuates right heart failure in acute pulmonary hypertension. Am J Respir Cell 33 Mol Biol 47 (2012) 379-86. 34 [47] J. Nopparat, J. Zhang, J.P. Lu, Y.H. Chen, D. Zheng, P.D. Neufer, et. al., a Wnt/beta-35 catenin modulator, reveals inducible mutagenesis promoting cancer cell survival 36 adaptation and metabolic reprogramming. Oncogene 34 (2015) 1542-52. 37 [48] A.R. Hemnes, E.L. Brittain, A.W. Trammell, J.P. Fessel, E.D. Austin, N. Penner, et. al., 38 Evidence for right ventricular lipotoxicity in heritable pulmonary arterial hypertension. Am 39 J Respir Crit Care Med 189 (2014) 325-34. 40 [49] S. Mazzotta, C. Neves, R.J. Bonner, A.S. Bernardo, K. Docherty, and S. Hoppler, 41 Distinctive Roles of Canonical and Noncanonical Wnt Signaling in Human Embryonic 42 Cardiomyocyte Development. Stem Cell Reports 7 (2016) 764-776. 43 [50] H. Laeremans, T.M. Hackeng, M.A. van Zandvoort, V.L. Thijssen, B.J. Janssen, H.C. 44 Ottenheiim, et. al., Blocking of frizzled signaling with a homologous peptide fragment of 45 wnt3a/wnt5a reduces infarct expansion and prevents the development of heart failure 46 after myocardial infarction. Circulation 124 (2011) 1626-35. 47 [51] M.A. Burke, S. Chang, H. Wakimoto, J.M. Gorham, D.A. Conner, D.C. Christodoulou, et.al., 48 Molecular profiling of dilated cardiomyopathy that progresses to heart failure. JCI Insight 49 1 (2016). 50 [52] H. Wang, Y. Lee, and C.C. Malbon, PDE6 is an effector for the Wnt/Ca2+/cGMP-signalling 51 pathway in development. Biochem Soc Trans 32 (2004) 792-6. 52 [53] J. Gomez-Arroyo, S. Mizuno, K. Szczepanek, B. Van Tassell, R. Natarajan, C.G. dos 53 Remedios, et. al., Metabolic gene remodeling and mitochondrial dysfunction in failing

- right ventricular hypertrophy secondary to pulmonary arterial hypertension. Circ Heart Fail 6 (2013) 136-44.
- 2 3 4 [54] S. Sprowl-Tanio, A.N. Habowski, K.T. Pate, M.M. McQuade, K. Wang, R.A. Edwards, et. al., Lactate/pyruvate transporter MCT-1 is a direct Wnt target that confers sensitivity to 3-bromopyruvate in colon cancer. Cancer Metab 4 (2016) 20.
- 5 6 7 [55] Nagy, II, A. Railo, R. Rapila, T. Hast, R. Sormunen, P. Tavi, et. al., Wnt-11 signalling controls ventricular myocardium development by patterning N-cadherin and beta-catenin . 8 9 expression. Cardiovasc Res 85 (2010) 100-9.
- 10

Figures and Tables




Figure 1 Relative RNA expression of WNT-related genes with differential transcription between pRV and RVF as noted in panels A-D.




Figure 2 ROR2 protein expression increases in RVF and correlates with hemodynamics
 (A) Dot plot demonstrating ROR2 protein expression among different groups and (B) lin

4

(A) Dot plot demonstrating ROR2 protein expression among different groups and (B) linear regression comparing ROR2 protein expression to RA:PCWP.





Figure 3 ROR2 expression correlates with increases in calpain expression and calpainmediated cleavage

4 (A) Western blots comparing expression of downstream targets between high and low ROR2 5 expressing RVF patients. (B) Logarithmic regressions comparing ROR2 expression to full

6 length, calpain cleaved, and phosphorylated FLNA



2 Proposed RVF model consisting of reactivation of a ROR2 fetal gene program with increasing RVF severity, which results in increased 3 calpain expression and activity leading to calpain-mediated cleavage of cytoskeleton structural proteins including FLNA.

- 1 Table 1 Clinical and demographic characteristics of right ventricular functional status by
- 2 cardiomyopathy type.

Clinical and demographic characteristics								
	Dilated Cardiomyopathy Ischemic Cardiomyopathy							
	RVF pRV			RVF	pRV			
Variables	n = 26	n = 47	Adj p	n = 9	n = 31	Adj p		
Age ^a	56.5	52.0	0.60	60.0	61.0	1.0		
	(49, 58)	(44, 60)		(56, 62)	(55, 63)			
Male	50%	72%	0.60	89%	87%	1.0		
Ethnicity	F 40/	0.40/	1.0	000/	0.40/	1.0		
Caucasian	54%	64%		89%	84%			
African American	38%	30%		0%	13%			
Other	8%	6%		11%	3%			
Heart weight (grams) ^a	471	465	0.87	570	552	1.0		
	(380, 549)	(421, 545)		(512, 625)	(455, 639)			
Weight (kg) ^a	76	80	1.0	93	82	0.92		
Body surface area (m ²) ^a	(73, 91) 1.90	(69, 92) 1.95	1.0	(84, 113) 2.19	<u>(75, 94)</u> 1.99	0.92		
Body surface area (III)	(1.8, 2.1)	(1.8, 2.1)	1.0	(2.0, 2.4)	(1.9, 2.2)	0.92		
#	49.0	67.3		55.4	53.5			
GFR [#]	(43, 65)	(55, 82)	0.10	(42, 56)	(44, 70)	1.0		
Diabetes Mellitus	32%	28%	1.0	56%	39%	1.0		
Insulin	15%	15%	1.0	44%	13%	1.0		
Thyroid medication	31%	6%	0.14	33%	16%	1.0		
Pacer	38%	21%	0.60	11%	6%	1.0		
ACE inhibitor	54%	51%	1.0	56%	58%	1.0		
ARB	31%	26%	1.0	22%	16%	1.0		
β-blocker	81%	94%	0.60	67%	87%	1.0		
Any Reverse Remodeling	100%	96%	1.0	100%	94%	1.0		
Calcium Channel Blocker	8%	6%	1.0	0%	0%	1.0		
Digoxin	50%	47%	1.0	22%	45%	1.0		
Diuretic	100%	87%	0.60	78%	90%	1.0		
Lipid lowering	42%	49%	1.0	67%	71%	1.0		
Milrinone	65%	72%	1.0	86%	71%	1.0		
RCA disease	4%	0%	N/A	56%	74%	1.0		
Prior CABG	0%	0%	N/A	67%	43%	1.0		
Prior Angioplasty	4%	0%	N/A	56%	52%	1.0		
Prior Stent	4%	0%	N/A	56%	52%	1.0		

3 ^aContinuous variables presented as median (interquartile range) and *p* value using two-tailed

Mann-Whitney U test. Categorical variables presented as percent and *p* value using Chi square
 2x2 contingency tables using pairwise deletion for any missing data. All *p* values are Benjamini-

6 Hochberg corrected, and none were less than 0.05. Abbreviations: angiotensin converting

7 enzyme inhibitor (ACE inhibitor), angiotensin receptor blocker (ARB), coronary artery bypass

8 grafting (CABG), glomerular filtration rate (GFR), and RCA (right coronary artery disease).

Differential RNA Expression between RVF and pRV								
Gene	RVF/pRV Fold Expression	Adj p						
AXIN2	1.30	0.07						
CREBBP	1.64	2.63x10⁻⁴						
DAAM2	1.15	0.46						
FZD1	1.10	0.55						
FZD7	1.19	0.46						
NFATC2	1.46	0.033						
NPPA	2.68	0.037						
ROR2	1.57	0.010						
SFRP1	0.90	0.31						
SFRP3	1.23	0.13						
WISP2	1.42	0.039						
WNT10B	1.03	0.55						

Genes which were differentially expressed in DCM and ICM pRV/RVF compared to NF using

2 3 Kruskal Wallis were selected for further analysis comparing RVF to pRV expression using

4 Benjamini Hochberg corrected Mann Whitney U test (p <0.05, bolded for significance).

Calpain	Linear	0.66	0.0018	1.8	0.011	
Phosphorylated PAK1	Logarithmic	0.83	1.4 x10 ⁻⁴	2.1	0.011	
Phospho:Total FLNA	Logarithmic	0.62	0.0025	9.7	0.0080	
FLNA 190 kDa	Logarithmic	0.25	0.077	7.6	0.0080	
FLNA 280 kDa	Logarithmic	0.67	0.0018	1.9	0.0080	
Spectrin 150 kDa	Logarithmic	0.17	0.10	2.7	0.015	
Spectrin 285 kDa	Logarithmic	0.17	0.10	1.4	0.0080	
Target	Relationship	Adjusted R ²	Adj P	Median Fold	Adj P	
-	ROR2 Exp	pression as Continuous	s Variable	High vs Low ROR2 Expression		
Increased	d ROR2 Expression Co	orrelates with Calpain-	Mediated Cleavage i	n Right Ventricular Failu	re	

 Table 3 Comparative analysis of human RVF with high and low ROR2 expression

3

1

4 Comparative analysis of high (n = 6) vs low (n = 6) ROR2 expressing RVF samples using ROR2 expression categorically (high vs

5 low) or as a continuous variable. As a continuous variable, target expression was assessed using both logarithmic and linear models

6 and the most significant model for each is displayed. In **bold** are comparisons that were statistically significant in both analyses.

SUPPLEMENTAL MATERIAL

- 1 2 **Supplemental Table 1** – RT-PCR primer sequences
- 2 3 4 Supplemental Table 2 – Clinical and demographic variables of combined pRV and RVF groups
- 5 Supplemental Table 3- Demographic variables of NF, pRV, and RVF groups for DCM and ICM
- 6 separately
- 7 Supplemental Table 4 – Fold changes by RT-PCR of WNT-related genes in DCM-pRV, DCM-
- 8 RVF, ICM-pRV, and ICM-RVF
- 9 Supplemental Figure 1 – Preliminary western blot analysis of candidate genes with differential
- 10 transcription between pRV and RVF
- 11

1 Supplemental Table 1

- 2 RT-PCR primer sequences for tested genes with references to known role in WNT signaling
- and/or cardiac pathology.
- 2 3 4

Gene Symbol	Forward	Reverse	Amplic on Size (bp)	Ref
AXIN2	TGTCCAGCAAAACTCTGAGG	GTGCAAAGACATAGCCAGAAC	129	[21]
CAPNS1	CACCCTGATCTGAAGACTGATG	CCTGCCACCTTTTGATGTTG	136	[29]
CREBBP	GCCGTTTACCATGAGATCCTTA	GGGTGGCAATGGAAGATGTA	122	[21]
CTNND2	CGGCATCTCCAAAAGCAAAG	AAGACGAGGCTACAAAGTGG	149	[47]
DAAM1	TCACCCAGAAATCACGTATCG	TCTGTGTTTGTCTGTGAGGTC	148	[48]
DAAM2	AGATGTTTTCAGCCTACCAGAG	ATGACCGACAGCTCTTTGAC	94	[21]
DKK3	AGGACACGCAGCACAAATTG	CCAGTCTGGTTGTTGGTTATCTT	196	[49]
FZD1	CATCGTCATCGCCTGCTACT	TAGCGTAGCTCTTGCAGCTC	89	[50]
FZD2	GGTGTCGGTGGCCTACAT	GAGAAGCGCTCGTTGCAC	66	[21]
FZD5	GCACAACCACATCCACTACG	GCCATGCCGAAGAAGTAGAC	81	[21]
FZD6	TTATGACCAGAGTATTGCCGC	AGTTTACGACAAGGTGGAACC	150	[21]
FZD7	CGCCTCTGTTCGTCTACCTC	TCATGATGGTGCGGATACGG	84	[51]
GAPDH	GGAAGGTGAAGGTCGGAGTC	GTTGAGGTCAATGAAGGGGTC	119	
GSK3B	CAAACAGACGCTCCCTGTG	TTCCAAAGGAATGGATATAGGC T	83	[21]
JNK1	CCAGGACTGCAGGAACGAGT	CCACGTTTTCCTTGTAGCCC	102	[40]
NFATC2	GAGGGGCTGTCAAAGCTCC	ACAGTTTTCCCCGTGATTCGG	163	[22]
NPPA	AGGATGGACAGGATTGGAGC	AAGTGTTGACAGGAAGCTGC	206	
NPPB	GCTGCTTTGGGAGGAAGATG	ATGAGTCACTTCAAAGGCGG	159	
PDE6B	AATAGGAAAGAGTGGAAGGCG	AGCAGGTTGAAGACTTGGG	148	[52]
PDK1	CTATGAAAATGCTAGGCGTCTGT	TGGGATGGTACATAAACCACTT G	120	[53]
ROCK2	TGATGGTTTCTATGGGCGAG	TGTTCCTACAAGTGAATCCGC	106	[21]
ROR2	AGAATATGGTTCACGACTGCG	GTTATGATTTGGGCTGTGCG	148	[37]
SFRP1	AAGTGTGACAAGTTCCCCG	TGGCCTCAGATTTCAACTCG	127	[18]
SFRP2	ATGATGATGACAACGACATAATG	ATGCGCTTGAACTCTCTCTGC	322	[21]
SFRP3	GGGACACTGTCAACCTCTATAC CA	GAGCCTTCCACCAAGAGTAATC TG	124	[22]
SLC16A1	CACCAGCGAAGTGTCATGGA	TCAAGTTGAAGGCAAGCCCA	224	[54]
WISP2	CATAAAGACTCACAGGTCCGC	GGCAGGTACATGGTGTCG	150	[51]
WNT1	CGGCGTTTATCTTCGCTATC	TTCGATGGAACCTTCTGAGC	77	[21]
WNT10B	GATACCCACAACCGCAATTC	GGGTCTCGCTCACAGAAGTC	110	[49]
WNT11	GGCCAAGTTTTCCGATGCTC	CACCCCATGGCACTTACACT	139	[55]
WNT5A	GCCCAGGTTGTAATTGAAGC	TGGCACAGTTTCTTCTGTCC	143	[22]

1 Supplemental Table 2

Clinical and demographic characteristics of combined DCM and ICM hemodynamic groups.

2 3

Clinical and Demographic Ch	aracteristics		4
	RVF	pRV	
Variables	n = 35	n = 78	Adj p
DCM	74%	60%	0.77
Age ^a	57 (52, 61)	55.5 (49, 62)	0.92
Male	60%	78%	0.37
Ethnicity			0.88
Caucasian	63%	72%	
African American	29%	23%	
Other	9%	5%	
Heart weight (grams) ^a	499 (388, 570)	498 (429, 609)	0.87
Weight (kg) ^a	84 (73, 97)	81 (70, 93)	0.88
Body surface area (m ²) ^a	1.96 (1.9, 2.2)	1.97 (1.8, 2.2)	0.88
GFR [#]	50.1 (40, 62)	62.2 (49, 81)	0.16
Diabetes Mellitus	38%	32%	0.89
Insulin	23%	16%	0.88
Thyroid medication	31%	10%	0.16
Pacer	31%	15%	0.37
ACE inhibitor	54%	55%	1.0
ARB	29%	22%	0.88
β-blocker	77%	92%	0.36
Any Remodeling	100%	96%	0.88
Calcium Channel Blocker	6%	4%	1.0
Digoxin	43%	46%	1.0
Diuretic	94%	90%	0.89
Lipid lowering	49%	59%	0.88
Milrinone	70%	73%	1.0

5

⁶ ^aContinuous variables presented as median (interquartile range) and *p* value using two-tailed 7 Mann-Whitney U test. Categorical variables presented as percent and *p* value using Chi square 8 contingency tables using pairwise deletion for any missing data. All *p* values are Benjamini-9 Hochberg corrected, and none were less than 0.05. Abbreviations: angiotensin converting 10 enzyme inhibitor (ACE inhibitor), angiotensin receptor blocker (ARB), coronary artery bypass 11 grafting (CABG), glomerular filtration rate (GFR), and RCA (right coronary artery disease).

1 **Supplemental Table 3** Demographic characteristics of NF compared to RV remodeling groups.

	NF	DCM-pRV	DCM-RVF		ICM-pRV	ICM-RVF	
Variables	n = 29	n= 47	n= 26	Adj P	n = 31	n= 9	Adj P
Age ^a	56 (45, 63)	52 (44, 60)	56.5 (48, 58)	0.34	61.0 (55, 63)	60.0 (56, 62)	0.56
Male	38%	72%	50%	0.047	84%	89%	4.6 x 10 ⁻⁴
Ethnicity				0.34			0.69
Caucasian	79%	64%	54%		78%	89%	
African American	14%	30%	38%		13%	0%	
Other	7%	6%	8%		3%	11%	
Weight (kg) ^a	69	80	76	0.83	82	93	0.56
	(62, 87)	(69, 92)	(73, 91)		(75, 94)	(84, 113)	
Body surface area (m ²) ^a	1.82	1.95	1.90	0.30	1.99	2.19	0.41
-	(1.7, 2.0)	(1.8, 2.1)	(1.8, 2.1)		(1.9, 2.2)	(2.0, 2.4)	

3

⁴ ^aContinuous variables presented as median (interquartile range) comparing NF/pRV/RVF separately for DCM and ICM using Kruskal-Wallis

5 test. Gender and ethnicity assessed using chi-square. All comparisons corrected using Benjamini-Hochberg

1 Supplemental Table 4


- 2 Differential WNT-related gene expression in Dilated and Ischemic Cardiomyopathy Right
- 3 Ventricle

Fold Enrichment in pRV and RVF in candidate WNT-related genes									
	DCM-pRV	DCM-RVF		ICM-pRV	ICM-RVF				
				•					
Gene	Fold	Fold	Adj p	Fold	Fold	Adj p			
	Natriuretic Peptides								
NPPA	16.2	27.9	9.56 x10 ⁻⁸	2.3	13.1	0.0023			
NPPB	9.2	15.8	0.026	1.9	4.4	0.34			
WNT Ligar			1						
WNT1	2.83	2.63	0.0022	2.09	2.35	0.050			
WNT10B	2.95	2.64	0.0075	2.22	2.58	0.018			
WNT11	1.02	1.19	0.89	0.99	2.30	0.046			
WNT5A	0.84	0.78	0.15	0.61	1.11	0.0025			
WNT recept	otors/co-rece	ptors							
FZD1	2.09	1.84	0.014	1.69	2.48	0.019			
FZD2	2.02	2.05	1.37 x10 ⁻⁴	1.21	1.42	0.083			
FZD5	0.84	0.90	0.34	0.79	1.94	0.0046			
FZD6	1.16	1.19	0.32	1.03	0.77	0.73			
FZD7	1.81	2.01	4.58 x10 ⁻⁷	1.85	2.54	3.31 x10 ⁻⁶			
ROR2	1.71	2.57	9.05 x10⁻ ⁶	1.64	4.32	6.83 x10 ⁻⁴			
WNT inhib	itors				• •				
DKK3	0.86	0.85	0.36	0.87	1.18	0.47			
SFRP1	1.67	1.34	0.0022	2.20	3.01	0.0012			
SFRP2	3.04	4.02	0.021	2.32	10.08	0.13			
SFRP3	4.26	4.37	1.10 x10 ⁻¹⁰	2.76	3.90	2.79 x10 ⁻⁵			
Cytoplasm	ic Signaling								
AXIN2	0.62	0.63	0.033	0.51	1.18	0.0013			
DAAM1	1.11	1.14	0.62	0.97	1.02	0.71			
DAAM2	0.52	0.39	0.0068	0.19	0.38	2.79 x10⁻⁵			
GSK3B	1.01	1.02	0.94	0.90	1.16	0.046			
NFATC2	1.30	1.57	0.032	1.44	4.48	0.0023			
Target Ger	nes								
CAPNS1	0.93	1.08	0.51	0.99	1.60	0.053			
CREBBP	1.12	1.38	0.033	0.95	3.33	6.83 x10 ⁻⁴			
CTNND2	1.19	0.92	0.56	0.72	2.35	0.56			
JNK1	1.44	1.35	0.0060	1.31	0.99	0.050			
PDE6B	1.08	1.10	0.50	0.88	1.19	0.15			
PDK1	1.57	1.70	1.37 x10 ⁻⁴	1.39	1.25	0.15			
ROCK2	0.83	0.80	0.069	0.73	0.94	0.023			
SLC16A1	1.18	1.08	0.069	0.87	0.84	0.99			
WISP2	0.39	0.43	8.90 x10 ⁻⁴	0.31	0.59	0.0095			

4 Differential gene expression analysis of DCM-pRV/RVF and ICM-pRV/RVF compared to NF

5 (normalized to 1) assessed for statistical significance using Benjamini-Hochberg corrected

- 1 Kruskal-Wallis p values. Genes with significant differential expression in both DCM and ICM
- 2 noted in bold.



1 Supplemental Figure 1

- 2 Preliminary western blot analysis comparing four representative samples from each group using the highest and lowest RA:PCWP for RVF
- 3 and pRV, respectively, and the lowest NPPA expression for NF to represent the extremes of each group.